clinical trial · NCT06990399
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK
Macular Edema Secondary to InflammationKSI-101Sham Comparator
brief summary
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants with Macular Edema Secondary to Inflammation (MESI)
started
Jul 30, 2025
primary completion
Feb 1, 2026
completion
Jul 1, 2027
last updated
Sep 10, 2025
official title
A Randomized, Double-masked, Sham-controlled, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tabirafusp Alfa (KSI-101) in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol